Skip Navigation LinksHome > May 2014 - Volume 21 - Issue 3 > Iron chelation: an update
Current Opinion in Hematology:
doi: 10.1097/MOH.0000000000000031

Iron chelation: an update

Sheth, Sujit

Free Access
Article Outline
Collapse Box

Author Information

Weill Cornell Medical College, New York, New York, USA

Correspondence to Sujit Sheth, MD, Professor of Clinical Pediatrics, Division of Pediatric Hematology and Oncology, Weill Cornell Medical College, 525 East 68th Street, P – 695, New York, NY 10065, USA. Tel: +1 212 746 3400; fax: +1 212 746 8609; e-mail:

Collapse Box


Purpose of review: This review provides an update on advances in the area of iron chelation therapy, including new indications and uses of currently available agents, and preliminary data on potential new agents in development.

Recent findings: Two new oral agents, deferasirox and deferiprone, have become available in the last 8 years. These have been used at higher doses, in combination with the older agent desferrioxamine, and recent trials’ data have shown efficacy in preventing or treating the toxicity associated with iron overload. Advances in measuring tissue iron noninvasively by magnetic resonance techniques have enhanced diagnostic capabilities and allowed for more precise measurement and monitoring of iron burden. The primary use of chelation has been transfusional iron overload. There is now an increasing body of evidence for the benefits of iron chelation in myelodysplasia, pre-stem cell transplantation, and potentially in the treatment of malignancies. Two new iron chelators are in development, one in phase 3 clinical trials and the other in preliminary animal studies.

Summary: The last decade has ushered in a new era in iron chelation therapy. Coupled with advances in tissue iron quantitation, there is tremendous promise of an individually tailored approach to chelation, and subsequent reduction in morbidity and mortality.

Back to Top | Article Outline


Over the last decade, iron chelation has undergone dramatic changes, with the approval by the US Food and Drug Administration of two novel, orally effective chelators, deferasirox (DFX) and deferiprone (DFP). Prior to this, parenteral desferrioxamine (DFO) was the only option available to individuals with transfusional hemosiderosis, and compliance was not optimal, resulting in increased morbidity and mortality. We have learned much about the efficacy, toxicity and long-term outcomes related to the use of these new chelators. Tremendous advances in our ability to quantify tissue iron by magnetic resonance techniques have facilitated a more rational and targeted approach, which has enabled individual tailoring of chelation. Improved protocols have been developed based on these data, including combination use, and are being implemented with success. Whereas the use of iron chelation was almost exclusively in transfusion-dependent patients with red cell disorders (mostly sickle cell anemia and thalassemia), newer indications have recently been better defined, such as non-transfusion-dependent thalassemia (NTDT) and myelodysplastic syndromes (MDS). There are data to suggest that chelation may inhibit tumorigenesis. Finally, there is also anticipation of two additional novel agents, one under study in animal models and the other already in phase 3 clinical trials. It must be kept in mind that though more data continue to be published related to iron overload in other transfusion-dependent conditions, most studies to date have been in transfusion-dependent thalassemia, and most recommendations for chelation are made based on these data.

Back to Top | Article Outline


Inherited hemochromatosis syndromes cause iron loading from increased intestinal absorption and are usually managed by serial phlebotomy. At present, iron chelation is used primarily for transfusional iron overload, which results in a variety of conditions, including hemoglobinopathies (thalassemia and sickle cell anemia), hemolytic anemias (pyruvate kinase deficiency, spherocytosis), inherited and acquired marrow failure syndromes (Diamond–Blackfan anemia (DBA), congenital dyserythropoietic anemias (CDA), and aplastic anemia), and premalignant and malignant conditions (MDS, following myelosuppressive chemotherapy or stem cell transplantation). With each milliliter of packed red cells (PRBCs) containing approximately 1 mg of iron, transfusional siderosis usually results following about 20 transfusions (appropriately dosed based on size, one or two units of PRBC at a time). With the body unable to excrete excess iron, tissue deposition results, with ensuing organ dysfunction and manifestations including cardiac arrhythmias, congestive heart failure, diabetes, other endocrinopathies and hepatic fibrosis. Cardiac failure is the most frequent cause of death. Toxicity of free iron is mediated by the free radicals generated through the Fenton reaction.

Back to Top | Article Outline


Box 1
Box 1
Image Tools

In the last decade, our ability to quantify tissue iron using magnetic techniques has enabled markedly improved monitoring of iron burden and the ability to tailor chelation therapy based on serial measurements of iron in tissues, primarily the liver and the heart. Two magnetic resonance (MR) methods exist for assessing the liver iron concentration (LIC), measurement of R2 (Ferriscan) and R2*. R2 appears to be more sensitive at higher iron concentrations than R2*. Traditionally, the ideal range for LIC has been thought to be 3–7 mg/g dry weight (based on the range in which heterozygotes for hereditary hemochromatosis have some excess iron but are asymptomatic) [1], but more recently there has been some advocacy for chelating down to near-normal LIC levels (<1.6 mg/g dry weight) [2]. MRI of the heart provides valuable functional information as well as assessment of myocardial iron by cardiac T2* (cT2*), with the desired range being above 20 milliseconds (ms). Cardiac T2* values under 10 ms are associated with high risk of both rhythm disturbances as well as contractile dysfunction [3]. More recent data has emphasized the lack of good correlation between the LIC and cT2* values. Differential deposition and chelation of iron is thought to be the reason, with the liver being first to load into and also easier to unload from [4]. The patient's underlying hematologic condition also seems to impact cardiac iron loading, with individuals with DBA seemingly more susceptible and those with sickle cell disease less so than patients with thalassemia major [5–7]. Finally, iron deposition in the pancreas [8] and pituitary [9] is being studied, with some prognostic implication, but these scans are not routinely done yet. There is very little debate on the lack of utility of the serum ferritin level in predicting the actual body iron burden, this marker showing poor correlation with liver and cardiac iron. Especially in inflammatory conditions such as sickle cell anemia, MDS and malignancy, elevation of this marker as an acute-phase reactant makes it even less reliable. MRI is now the recommended method of assessing iron in the tissues and this data should be used to make decisions regarding initiation and tailoring of chelation therapy.

Back to Top | Article Outline


At present, three iron chelators are approved for clinical use. This section will focus on the most recent trials which have used these agents, either singly or in combination. While information related to long-term efficacy and safety is available for DFO, such data are not available yet for the newer agents, DFX and DRP (see Table 1).

Table 1
Table 1
Image Tools
Back to Top | Article Outline

This hexadentate molecule, which binds iron stably in a 1 : 1 ratio, has been in use for over 40 years and remains a valuable agent despite the cumbersome nature of its parenteral use. It has a mild toxicity profile, with local skin reactions and infections being the most common side effects. Ototoxicity, nephrotoxicity and visual impairment are also rare. While still used exclusively by some individuals, the availability of the oral agents has resulted in relegation of this agent to patients who have a high iron burden, in whom it is used in combination with one of the other agents, and in individuals who need but are not able to tolerate higher doses of these agents.

Back to Top | Article Outline

This tridentate molecule, which binds iron highly specifically in a 2 : 1 ratio, has been in clinical use for the last 8 years. Its advantages are oral administration, a longer half-life allowing for once-daily dosing and a relatively good toxicity profile. Common mild side-effects include transient skin rashes and gastrointestinal upset. Hepatic and renal toxicity may be seen at higher doses, and other rare toxicities include a Fanconi-like syndrome of hypophosphatemia, and cataracts. Initially used at doses of 20–30 mg/kg/day, studies have shown that it is safe at doses upto 40 mg/kg/day in individuals with high iron burden [10]. In longer-term studies over 5 years, DFX is able to reduce LIC in most patients with transfusion-dependent beta-thalassemia, when administered at a dose of 20 mg/kg/day or above, and is well tolerated without major toxicity [11]. It has been demonstrated to effectively reduce myocardial iron by T2* in the short and long term [12,13], though this seems to be dependent on the total body iron burden. In fact, some individuals with a very high LIC had some worsening of myocardial T2*. Interestingly, these studies did not show an improvement in cardiac function in the short term. The use of DFX for individuals with poor cardiac function is still being investigated.

Back to Top | Article Outline

A bidentate chelator which binds iron in a 3 : 1 ratio, DFP was approved for use in the USA just 2 years ago, though it had been in use in other parts of the world for several years. It has a shorter half-life, requiring administration three times a day in doses of 75–100 mg/kg/day. Safety remains a concern with this agent, with significant toxicities including neutropenia, rare instances of agranulocytosis and arthropathy, all requiring interruption of therapy. Gastrointestinal and hepatic toxicity do not appear to be major limiting factors, with initial reports of hepatic fibrosis [14] not being confirmed in subsequent studies [15]. The efficacy of DFP in reducing LIC is variable, but is thought to be comparable to that of DFO [16]. The primary advantage of this agent appears to be its ability to enter cardiac myocytes and remove iron from these cells, resulting in improvement of cardiac T2*, myocardial function and a reduction in morbidity and mortality [17,18].

Back to Top | Article Outline


In situations when intensification of chelation is required for individuals with a very high burden, or with the occurrence of dose-limiting toxicity with single agents, combination therapy is been used to increase iron excretion and reduce adverse effects. Moreover, with the improved means of quantifying tissue iron, tailoring chelation to individual needs based on the differential distribution of iron, as well as the proposed synergy between agents, has led to combinations of the chelators described above (see Table 2).

Table 2
Table 2
Image Tools
Back to Top | Article Outline
Desferrioxamine and deferiprone

DFO and DFP is the most extensively studied combination. Several different dosing schedules have been used, all of which seem to show a significant decline in serum ferritin [19,20], and more importantly, the combination demonstrated great efficacy at purging cardiac iron [21]. This is likely based on a hypothesis that DFP is able to enter cardiac myocytes and shuttle iron out into the plasma for DFO to bind and excrete [22]. A more recent study comparing this combination with DFO alone in thalassemia patients with heart failure did not demonstrate benefit to using the combination [23].

Back to Top | Article Outline
Desferrioxamine and deferasirox

Data on this combination are limited. In the animal model, it is safe and effective [24], and case reports and series in humans have confirmed these findings [25,26]. It does not seem that there is synergy, as with the previous combination, but the longer half-life of DFX would provide more continuous chelation and, therefore, possibly increased iron excretion overall. Dosing regimens have varied from sequential to concomitant, with no data-based consensus on an optimal regimen. More recently, a prospective study in 22 patients treated concomitantly with both agents demonstrated a significant improvement in systemic (as measured by LIC) and myocardial iron, also reducing the toxic labile plasma iron species [27].

Back to Top | Article Outline
Deferasirox and deferiprone

DFX and DFP would be the ideal combination as both agents are orally administered. However, once again, there are limited case report data on this combination [28,29]. Data from animal models in which the combination has been used to chelate other metals such as mercury, cadmium, aluminum and chromium have shown few toxic effects.

Back to Top | Article Outline


Two new agents are currently under study, but at very different levels of development. These are discussed briefly below:

Back to Top | Article Outline

Previously termed FBS0701, this is a desferrithiocin derivative, a tridentate chelator, currently in phase 2/3 trials in several centers around the world. In the phase 1b study, it was found to be safe at four escalating doses, with a mean half-life of 16.2–21.3 h. It was administered once-daily for 7 days, with toxicity including headache, gastrointestinal symptoms and a mild prolongation of the QTc in one individualwith sickle cell disease [30]. Current phase 2/3 studies in individuals with thalassemia and sickle cell anemia with transfusional siderosis are underway, but results of these trials are still some time away.

Back to Top | Article Outline

Development of this tridentate chelator stalled initially when the animal models (rodent and primate) developed severe nephrotoxicity. Several modifications in the chemical structure of the molecule with numerically designated derivatives 2, 3, 6, 7, 8, 9 and 10 have been studied in animals [31,32]. Specifically, each ligand's iron-clearing efficacy (ICE), tissue distribution, biliary ferrokinetics and tissue iron reduction profile are being analyzed in both models. Once the appropriate molecule has been synthesized, there is hope that it will move into human clinical trials.

Back to Top | Article Outline


Traditionally, chelation has been used almost entirely for secondary hemosiderosis related to regular transfusions in individuals with inherited red cell abnormalities, predominantly transfusion-dependent thalassemia (major), sickle cell disease for treatment or prevention of stroke, and other conditions such as DBA and CDA. More recently, the scope of chelation has broadened considerably, to include a variety of other disorders, some with iron overload and others in which it appears that iron may play an important role in the pathophysiology of that condition.

Back to Top | Article Outline
Non-transfusion-dependent thalassemia

Individuals with the phenotype of thalassemia intermedia, including those with the various globin gene mutations, are not dependent on regular transfusions, but are at risk for developing iron overload as well. In addition to sporadic transfusions, these individuals load iron through increased intestinal absorption, mediated by the relative deficiency of hepcidin as a result of ineffective erythropoiesis [33]. The degree of iron loading depends on the number of transfusions and the degree of ineffective erythropoiesis, and is not predictable in these patients. A recent report confirms that the serum ferritin level, which was previously used exclusively to monitor these individuals, underestimates the degree of iron loading, and recommends MRI for a more accurate picture [34]. DFX at lower dose has been used effectively to reduce the iron burden in these patients in the short term, though a longer-term regimen has not been devised yet [35▪].

Back to Top | Article Outline
Myelodysplastic syndromes

There has been much attention focused on iron chelation in patients with MDS in the last few years. Although the major cause of siderosis is transfusional, ineffective erythropoiesis does contribute as well. No prospective studies of the effect of iron overload exist to date in this population, but there is some evidence of the benefit of chelation. In contrast to most patients with the transfusion-dependent anemias, those with MDS are older and have other preexisting morbidities, which may be exacerbated by the iron overload. A review of the epidemiology of MDS, the risk stratification, transfusion dependence rates and iron overload complications was published recently [36]. Several studies have demonstrated the improved survival of individuals with a lower body iron burden [37], whereas others have found no correlation [38]. However, the majority of these studies relied on the serum ferritin level as the marker for iron overload. Those patients who received regular transfusions had higher rates of cardiac events than those who did not. Interestingly, several reports found no significant increase in iron deposition in the heart of these patients. The mechanism by which iron reduction may improve survival is not clear, possibly being related to improvement in organ function. In addition, there are data suggesting that chelation therapy and reduction in iron overload may actually improve tri-lineage hematopoiesis in these patients as well, with a reduction in transfusion requirements in many patients, some even achieving transfusion independence [39–43], believed to be related to a reduction in oxidative stress, increase in erythropoietin levels or inhibition of NF-kB [44].

In the past, a minority of patients with MDS and transfusional siderosis received infusions of DFO. Systematic data are not available for the efficacy of chelation in those patients. More recently, systematic, prospective trials have used DFX in these patients with some success [45,46,47▪]. Most studies reported a decrease in serum ferritin levels, but the major studies also reported that approximately 50% of patients discontinued chelation, some as a result of side-effects (similar to those described in the section on chelators) and others because of progression of MDS to leukemia. Future studies will focus on better evaluation of both tissue iron parameters as well as organ function in an effort to further define the role of chelation in MDS.

Back to Top | Article Outline
Pre-stem cell transplantation

The role of chelation before stem cell transplantation in patients with transfusional iron overload has also been further clarified. Previous studies, using serum ferritin values to define iron overload, showed improved outcomes in individuals with lower levels [48–50]. However, a recent prospective study in patients with MDS or acute leukemia undergoing stem cell transplantation found no correlation between iron burden, as measured by MRI methods, and mortality, relapse, or graft-versus-host disease [51]. Hyperferritinemia still correlated with poorer outcomes, raising the question of the true implication of this marker – inflammation or iron overload. It appears that the role of chelation in the pretransplant setting is now less certain than previously thought.

Back to Top | Article Outline


Significant advances in tissue iron quantitation by MRI techniques have changed our approach to transfusional iron overload in the last decade. Moreover, our understanding of the differential tissue deposition of iron and our ability to study the effects of non-transferrin bound iron, the labile plasma iron pool and reactive oxygen species in greater depth have allowed for a more rational approach to chelation. The introduction of two new oral iron chelators has improved outcomes, likely in most part because of improved compliance with therapy compared with the original parenteral chelator. Phase 3 and 4 trials of these chelators, and longitudinal studies of cohorts of patients have provided better protocols for dose modification, combination therapy and switching of chelators, all resulting in improved care of patients with transfusional iron overload and a reduction in morbidity and mortality. The promise of new chelators in development can be viewed with additional optimism for a new age in iron chelation therapy.

Back to Top | Article Outline



Back to Top | Article Outline
Conflicts of interest

The author declares no conflicts of interest in the preparation of this work. No grants or external funding supported this work.

The author is currently participating in the Phase 3 trial of the new chelator discussed (SSP-004184). No information from that participation is part of this article, and only already published data are presented related to this chelator.

Back to Top | Article Outline


Papers of particular interest, published within the annual period of review, have been highlighted as:

▪ of special interest

▪▪ of outstanding interest

Back to Top | Article Outline


1. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739–761.

2. Farmaki K, Tzoumari I, Pappa C, et al. Normalization of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2009; 148:466–475.

3. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120:1961–1968.

4. Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116:537–543.

5. Fung EB, Harmatz PR, Lee PD, et al. Increased prevalence of iron-overload associated endocrinopathy in thalassaemia versus sickle-cell disease. Br J Haematol 2006; 135:574–582.

6. Wood JC, Tyszka M, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood 2004; 103:1934–1936.

7. Roggero S, Quarello P, Vinciguerra T, et al. Severe iron overload in Blackfan–Diamond anemia: a case–control study. Am J Hematol 2009; 84:729–732.

8. Noetzli LJ, Mittelman SD, Watanabe RM, et al. Pancreatic iron and glucose dysregulation in thalassemia major. Am J Hematol 2012; 87:155–160.

9. Noetzli LJ, Panigrahy A, Mittelman SD, et al. Pituitary iron and volume predict hypogonadism in transfusional iron overload. Am J Hematol 2012; 87:167–171.

10. Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of 30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147:752–759.

11. Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years’ follow-up. Blood 2011; 118:884–893.

12. Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115:2364–2371.

13. Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica 2012; 97:842–848.

14. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339:417–423.

15. Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100:1566–1569.

16. Maggio A, D’Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28:196–208.

17. Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107:3738–3744.

18. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107:3733–3737.

19. Origa R, Bina P, Agus A, et al. Combined therapy with deferiprone and desferrioxamine in thalassemia major. Haematologica 2005; 90:1309–1314.

20. Kattamis A, Ladis V, Berdousi H, et al. Iron chelation treatment with combined therapy with deferiprone and deferoxamine: a 12-month trial. Blood Cells Mol Dis 2006; 36:21–25.

21. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo- controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115:1876–1884.

22. Link G, Konijn AM, Breuer W, et al. Exploring the ‘iron shuttle’ hypothesis in chelation therapy: effects of combined deferoxamine and deferiprone treatment in hypertransfused rats with labeled iron stores and in iron-loaded rat heart cells in culture. J Lab Clin Med 2001; 138:130–138.

23. Porter JB, Wood J, Olivieri N, et al. Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone. J Cardiovasc Magn Reson 2013; 15:38.

24. Otto-Duessel M, Brewer C, Gonzalez I, et al. Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload. Acta Haematol 2008; 120:123–128.

25. Jetsrisuparb A, Komvilaisak P, Wiangnon S, Jetsrisuparb C. Retrospective study on the combination of desferrioxamine and deferasirox for treatment of iron-overloaded thalassemic patients: first evidence of more than 2 years. J Pediatr Hematol Oncol 2010; 32:400–403.

26. Voskaridou E, Komninaka V, Karavas A, et al. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. Transfusion 2013; [Epub ahead of print].

27. Lal A, Porter J, Sweeters N, et al. Combined chelation therapy with deferasirox and deferoxamine in thalassemia. Blood Cells Mol Dis 2013; 50:99–104.

28. Balocco M, Carrara P, Pinto V, Forni GL. Daily alternating deferasirox and deferiprone therapy for ‘hard-to-chelate’ beta-thalassemia major patients. Am J Hematol 2010; 85:460–461.

29. Berdoukas V, Carson S, Nord A, et al. Combining two orally active iron chelators for thalassemia. Ann Hematol 2010; 89:1177–1178.

30. Rienhoff HY Jr, Viprakasit V, Tay L, et al. A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload. Haematologica 2011; 96:521–525.

31. Bergeron RJ, Wiegand J, Bharti N, et al. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity. Biometals 2011; 24:239–258.

32. Bergeron RJ, Wiegand J, Bharti N, McManis JS. Substituent effects on desferrithiocin and desferrithiocin analogue iron-clearing and toxicity profiles. J Med Chem 2012; 55:7090–7103.

33. Galanello R. Recent advances in the molecular understanding of nontransfusion-dependent thalassemia. Blood Rev 2012; 26 (Suppl. 1):S7–S11.

34. Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in nontransfusion-dependent thalassemia: a clinical perspective. Blood Rev 2012; 26 (Suppl. 1):S16–S19.

35▪. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in nontransfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol 2013; 92:1485–1493.

This is a new indication for iron chelation. This study reviews the subject and the results of the trial.

36. Leitch HA. Controversies surrounding iron chelation therapy for MDS. Blood Rev 2011; 25:17–31.

37. Malcovati L, Della Porta MG, Cazzola M. Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 2006; 91:1588–1590.

38. Kao JM, McMillan A, Greenberg PL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008; 83:765–770.

39. Chee CE, Steensma DP, Wu W, et al. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol 2008; 83:611–613.

40. Jensen PD, Jensen IM, Ellegaard J, et al. Desferrioxamine treatment reduces blood transfusion requirements in patients with myelodysplastic syndrome. Br J Haematol 1992; 80:121–124.

41. Messa E, Cilloni D, Messa F, et al. Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis. Acta Haematol 2008; 120:70–74.

42. Oliva EN, Ronco F, Marino A, et al. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion 2010; 50:1568–1570.

43. Guariglia R, Martorelli MC, Villani O, et al. Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. Leuk Res 2011; 35:566–570.

44. Kikuchi S, Kobune M, Iyama S, et al. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox. Free Radic Biol Med 2012; 53:643–648.

45. Gattermann N, Finelli C, Porta MD, et al. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: results from the large 1-year EPIC study. Leuk Res 2010; 34:1143–1150.

46. List AF, Baer MR, Steensma DP, et al. Deferasirox reduces serum ferritin and labile plasma iron in RBC transfusion-dependent patients with myelodysplastic syndrome. J Clin Oncol 2012; 30:2134–2139.

47▪. Nolte F, Hochsmann B, Giagounidis A, et al. Results from a 1-year, open-label, single arm, multicenter trial evaluating the efficacy and safety of oral deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload. Ann Hematol 2013; 92:191–198.

MDS is also a potential new indication for chelation. This study discusses the rationale and results of this trial.

48. Altes A, Remacha AF, Sureda A, et al. Iron overload might increase transplant-related mortality in haematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29:987–989.

49. Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109:4586–4588.

50. Mahindra A, Bolwell B, Sobecks R, et al. Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell trans- plantation. Br J Haematol 2009; 146:310–316.

51. Armand P, Sainvil MM, Kim HT, et al. Pretransplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplant 2013; 48:146–147.


combination therapy; deferasirox; deferiprone; new uses

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.